Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.76 |
| ▸ | GAA | P10253 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418775 | 0.86 | KDM4E (1.00) | KDM4EGAAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL288141 | 0.86 | KDM4E (0.78) | KDM4EGAAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL298290 | 0.84 | KDM4E (1.00) | KDM4EGAAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL290132 | 0.80 | KDM4E (1.00) | KDM4EGAAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5727580 | 0.78 | KDM4E (0.58) | KDM4EGAAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL288846 | 0.78 | KDM4E (0.84) | KDM4EGAAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL290222 | 0.77 | KDM4E (0.64) | KDM4EGAAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL4167344 | 0.77 | ALDH1A1 (0.67) | KDM4EGAAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL892990 | 0.76 | SMN1; SMN2 (0.76) | KDM4EGAAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL289704 | 0.75 | KDM4E (0.79) | KDM4EGAAALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790723-B2 | Thiazole derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-20050222160-A1 | Thiazole derivatives as phosphodiesterase iv inhibitors | MERCK PATENT GMBH (DE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222160-A1 | Thiazole derivatives as phosphodiesterase iv inhibitors | PDE3B, PDE4B, PDE4A | KDM4E 1126/4885GAA 462/4885ALDH1A1 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.